<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02962739</url>
  </required_header>
  <id_info>
    <org_study_id>16-0972</org_study_id>
    <nct_id>NCT02962739</nct_id>
  </id_info>
  <brief_title>The Cellular Pharmacology of F-TAF in Dried Blood Spots</brief_title>
  <acronym>TAF-DBS</acronym>
  <official_title>The Cellular Pharmacology of F-TAF in Dried Blood Spots</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adherence to daily dosing is very important for how well Emtricitabine/Tenofovir Alafenamide&#xD;
      (F/TAF) works for treatment of chronic human immunodeficiency virus (HIV), or prevention of&#xD;
      HIV acquisition. Methods to measure medication adherence to Tenofovir disoproxil fumarate&#xD;
      (tenofovir DF, TDF), a similar but different prodrug of tenofovir, have been developed but&#xD;
      cannot be extrapolated to F-TAF. By measuring F-TAF (the drug) and metabolites in the blood&#xD;
      cells and dried blood spots, the study plans to see if these results predict adherence to&#xD;
      taking the drug. The goal of this study is to vary the amount of F-TAF dosing and see if the&#xD;
      drug levels in dried blood spots (DBS) change in a predictable way. This study will mimic&#xD;
      different levels of adherence (33%, 67%, and 100% of daily dosing) using directly observed&#xD;
      therapy (DOT) to establish the relationship between F-TAF in dried blood spots and adherence.&#xD;
      Investigators will also measure drug in hair clippings to see if hair or DBS are a better&#xD;
      predictor of adherence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Actual">May 22, 2019</completion_date>
  <primary_completion_date type="Actual">May 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady State Concentrations of TFV-DP for Different Dosing Patterns of Descovy</measure>
    <time_frame>Assessed weekly for 9 months</time_frame>
    <description>Tenofovir diphosphate (TFV-DP) concentrations in dried blood spots (DBS) respective to dosing regimens of 33%, 67%, 100% of daily dosing.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>33%/67% dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>33%/100% dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>67%/33% dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>67%/100% dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100%/33% dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100%/67% dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>emtricitabine 200 mg/tenofovir alafenamide 25mg</intervention_name>
    <description>1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg</description>
    <arm_group_label>100%/33% dosing</arm_group_label>
    <arm_group_label>100%/67% dosing</arm_group_label>
    <arm_group_label>33%/100% dosing</arm_group_label>
    <arm_group_label>33%/67% dosing</arm_group_label>
    <arm_group_label>67%/100% dosing</arm_group_label>
    <arm_group_label>67%/33% dosing</arm_group_label>
    <other_name>Descovy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ambulatory 18-59 year old adults. Enrollment will proceed without the need to meet&#xD;
             specific race/gender targets, but balanced gender and African-Americans and Latino&#xD;
             representation will be sought.&#xD;
&#xD;
          2. Ability to comply with study procedures, including directly observed dosing visits and&#xD;
             availability and use of video streaming technology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to give informed consent&#xD;
&#xD;
          2. Pregnancy or plan to become pregnant in the next 12 months or unwillingness to use&#xD;
             birth control&#xD;
&#xD;
          3. Current breastfeeding&#xD;
&#xD;
          4. High risk of HIV-1 infection, for example:&#xD;
&#xD;
               -  sexually active with an HIV infected partner;&#xD;
&#xD;
               -  men who have sex with men who may engage in condomless intercourse with&#xD;
                  HIVinfected partners, or&#xD;
&#xD;
               -  partner of unknown status during the study;&#xD;
&#xD;
               -  males or females who exchange sex for money, shelter, or gifts;&#xD;
&#xD;
               -  active injection drug use or during the last 12 months;&#xD;
&#xD;
               -  newly diagnosed sexually transmitted infections in last 6 months&#xD;
&#xD;
          5. Positive screening HIV+ ELISA or suspected acute HIV infection in the opinion of the&#xD;
             clinician. Example signs and symptoms of acute HIV infection include combinations of:&#xD;
&#xD;
               -  fever,&#xD;
&#xD;
               -  headache,&#xD;
&#xD;
               -  fatigue,&#xD;
&#xD;
               -  arthralgia,&#xD;
&#xD;
               -  vomiting,&#xD;
&#xD;
               -  myalgia, .&#xD;
&#xD;
               -  diarrhea,&#xD;
&#xD;
               -  pharyngitis,&#xD;
&#xD;
               -  rash,&#xD;
&#xD;
               -  night sweats, and&#xD;
&#xD;
               -  adenopathy (cervical or inguinal)&#xD;
&#xD;
          6. Positive Hepatitis B Virus (HBV) surface antigen test at screening&#xD;
&#xD;
          7. Active psychiatric illness, social condition, or alcohol/drug abuse that, in the&#xD;
             opinion of the investigators, would interfere with study requirements.&#xD;
&#xD;
          8. Glomerular Filtration Rate (GFR) estimate &lt; 60 ml/min (MDRD equation).&#xD;
&#xD;
          9. Urine dipstick protein ≥ 2+&#xD;
&#xD;
         10. Total bilirubin and/or hepatic transaminases (ALT and AST) ≥ 2.5x upper limit of&#xD;
             normal&#xD;
&#xD;
         11. Absolute neutrophil count ≤ 1,500/mm3, platelets count ≤ 100,000/mm3, or hemoglobin ≤&#xD;
             10 g/dL.&#xD;
&#xD;
         12. Symptomatic hemoglobinopathies or active hemolysis.&#xD;
&#xD;
         13. History of pathological, non-traumatic bone fractures&#xD;
&#xD;
         14. Any laboratory value or uncontrolled medical conditions that, in the opinion of the&#xD;
             investigators, would interfere with the study conditions such as, heart disease and/or&#xD;
             cancer.&#xD;
&#xD;
         15. Prohibited concomitant medications are:&#xD;
&#xD;
               -  investigational agents (within 30 days of enrollment),&#xD;
&#xD;
               -  aminoglycosides,&#xD;
&#xD;
               -  ganciclovir/valganciclovir,&#xD;
&#xD;
               -  chronic high-dose acyclovir/valacyclovir (&gt;800mg acyclovir or &gt; 500mg&#xD;
                  valacyclovir for 7 days),&#xD;
&#xD;
               -  cyclosporine, amphotericin B, foscarnet, and cidofovir, and products with same or&#xD;
                  similar active ingredients as the study medications including TRUVADA®, ATRIPLA®,&#xD;
                  COMPLERA®, EMTRIVA®, VIREAD®; or drugs containing lamivudine or adefovir, which&#xD;
                  are close analogs of FTC and tenofovir, respectively.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Anderson, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado- Anschutz Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Yager J, Castillo-Mancilla J, Ibrahim ME, Brooks KM, McHugh C, Morrow M, McCallister S, Bushman LR, MaWhinney S, Kiser JJ, Anderson PL. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. J Acquir Immune Defic Syndr. 2020 Jul 1;84(3):323-330. doi: 10.1097/QAI.0000000000002354.</citation>
    <PMID>32539288</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <results_first_submitted>February 6, 2020</results_first_submitted>
  <results_first_submitted_qc>January 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/39/NCT02962739/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>33%/67% Dosing</title>
          <description>The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).&#xD;
emtricitabine 200 mg/tenofovir alafenamide 25mg: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg</description>
        </group>
        <group group_id="P2">
          <title>33%/100% Dosing</title>
          <description>The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.&#xD;
emtricitabine 200 mg/tenofovir alafenamide 25mg: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg</description>
        </group>
        <group group_id="P3">
          <title>67%/33% Dosing</title>
          <description>The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).&#xD;
emtricitabine 200 mg/tenofovir alafenamide 25mg: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg</description>
        </group>
        <group group_id="P4">
          <title>67%/100% Dosing</title>
          <description>67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.&#xD;
emtricitabine 200 mg/tenofovir alafenamide 25mg: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg</description>
        </group>
        <group group_id="P5">
          <title>100%/33% Dosing</title>
          <description>The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.&#xD;
emtricitabine 200 mg/tenofovir alafenamide 25mg: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg</description>
        </group>
        <group group_id="P6">
          <title>100%/67% Dosing</title>
          <description>67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.&#xD;
emtricitabine 200 mg/tenofovir alafenamide 25mg: 1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are not stratified based on dosing regimen. Dosing Arms were combined, regardless of dosing regimen order (i.e. all 33%, regardless if 33% regimen followed by other regimen (100% or 67%), or other regimen (100% or 67%) followed by 33%) to be consistent with data collection, protocol subject randomization and journal publications. Combined arms best categorize the study, population, and data.</population>
      <group_list>
        <group group_id="B1">
          <title>All Dosing Regimens</title>
          <description>Baseline characteristics for all 35 subjects analyzed. Baseline characteristics not stratified based on dosing regimen. Arms were combined to be consistent with protocol subject randomization. Subjects were randomized to one of six arms. Combined arms best categorize the study, population, and data.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>3 subjects withdrew- only 35 of 38 enrolled were analyzed</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>3 subjects withdrew- only 35 of 38 enrolled were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>38 subjects started study procedures. Of 38, 3 withdrew thus only 35 were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Steady State Concentrations of TFV-DP for Different Dosing Patterns of Descovy</title>
        <description>Tenofovir diphosphate (TFV-DP) concentrations in dried blood spots (DBS) respective to dosing regimens of 33%, 67%, 100% of daily dosing.</description>
        <time_frame>Assessed weekly for 9 months</time_frame>
        <population>34 participants received 2 of 3 dosing regimens and 1 participant only completed through week 8 of the second regimen, resulting in a total of 69 observations.</population>
        <group_list>
          <group group_id="O1">
            <title>DOT 33%</title>
            <description>33% of daily dosing; dosing on day one followed by skipped doses on days two and three, repeated for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>DOT 67%</title>
            <description>67% of daily dosing; dosing on days one and two, skipped dose on day three, repeated for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>DOT 100%</title>
            <description>100% of daily dosing:dosing every day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Concentrations of TFV-DP for Different Dosing Patterns of Descovy</title>
          <description>Tenofovir diphosphate (TFV-DP) concentrations in dried blood spots (DBS) respective to dosing regimens of 33%, 67%, 100% of daily dosing.</description>
          <population>34 participants received 2 of 3 dosing regimens and 1 participant only completed through week 8 of the second regimen, resulting in a total of 69 observations.</population>
          <units>fmol/punch</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="657" spread="186"/>
                    <measurement group_id="O2" value="1451" spread="501"/>
                    <measurement group_id="O3" value="2381" spread="601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time of consenting to study exit (Week 36 or earlier), Max 10 months.</time_frame>
      <desc>AEs were graded per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0, November, 2014. Available: http://rsc.tech-res.com/safetyandpharmacovigilance/.&#xD;
Arms were combined as Descovy was FDA approved for daily use (100% dosing) at the time of study initiation- no arm was considered to be more at risk for AEs than another.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Subjects</title>
          <description>At study initiation Descovy was FDA approved for daily dosing (100% daily dosing). Thus, the AE profile was already established for 100% dosing and AE rates in the lower doses (33% and 67%) would not exceed the established rate for daily dosing (100%). This study was not designed to collect new safety data or to update the established AE/Safety profiles for Descovy. Therefore AE data was combined for all dosing regimens.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>traumatic leg fracture</sub_title>
                <description>traumatic leg fracture unrelated to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pleurisy VS costochondritis</sub_title>
                <description>Left-sided chest pain, pain was exertional and with movement. ED ruled out PE and cardiac issues, and thought it was muscular and potentially &quot;inflammatory&quot; in etiology. Pain resolved and no reason to believe related to study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Labs</sub_title>
                <counts group_id="E1" events="29" subjects_affected="15" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cold Symptoms</sub_title>
                <counts group_id="E1" events="62" subjects_affected="31" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter Anderson</name_or_title>
      <organization>University of Colorado | Skaggs School of Pharmacy and Pharmaceutical Sciences</organization>
      <phone>3037246128</phone>
      <email>peter.anderson@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

